ImmunityBio, Inc. announced the treatment of patients in the U.S. with ANKTIVA for BCG-unresponsive bladder cancer. The FDA approved this immunotherapy on April 22, 2024.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & History - Yahoo Finance
